Your browser doesn't support javascript.
loading
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life.
Davé, Emma; Durrant, Oliver; Dhami, Neha; Compson, Joanne; Broadbridge, Janice; Archer, Sophie; Maroof, Asher; Whale, Kevin; Menochet, Karelle; Bonnaillie, Pierre; Barry, Emily; Wild, Gavin; Peerboom, Claude; Bhatta, Pallavi; Ellis, Mark; Hinchliffe, Matthew; Humphreys, David P; Heywood, Sam P.
Afiliación
  • Davé E; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Durrant O; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Dhami N; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Compson J; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Broadbridge J; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Archer S; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Maroof A; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Whale K; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Menochet K; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Bonnaillie P; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Barry E; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Wild G; PV Supply and Technology Solutions, UCB Biopharma UK, Slough, UK.
  • Peerboom C; PV Supply and Technology Solutions, UCB Biopharma SRL, Braine-l'Alleud, Belgium, EU.
  • Bhatta P; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Ellis M; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Hinchliffe M; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Humphreys DP; Early Solutions, UCB Biopharma UK, Slough, UK.
  • Heywood SP; Early Solutions, UCB Biopharma UK, Slough, UK.
MAbs ; 15(1): 2160229, 2023.
Article en En | MEDLINE | ID: mdl-36788124
ABSTRACT
TrYbe® is an Fc-free therapeutic antibody format, capable of engaging up to three targets simultaneously, with long in vivo half-life conferred by albumin binding. This format is shown by small-angle X-ray scattering to be conformationally flexible with favorable 'reach' properties. We demonstrate the format's broad functionality by co-targeting of soluble and cell surface antigens. The benefit of monovalent target binding is illustrated by the lack of formation of large immune complexes when co-targeting multivalent antigens. TrYbes® are manufactured using standard mammalian cell culture and protein A affinity capture processes. TrYbes® have been formulated at high concentrations and have favorable drug-like properties, including stability, solubility, and low viscosity. The unique functionality and inherent developability of the TrYbe® makes it a promising multi-specific antibody fragment format for antibody therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos Fc de Inmunoglobulinas / Fragmentos de Inmunoglobulinas Límite: Animals Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fragmentos Fc de Inmunoglobulinas / Fragmentos de Inmunoglobulinas Límite: Animals Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
...